Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Next Previous
Trial Profile

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verteporfin (Primary) ; Ranibizumab
  • Indications Polypoidal choroidal vasculopathy
  • Focus Therapeutic Use
  • Acronyms EVEREST II
  • Sponsors Novartis

    • Most Recent Events

    • 01 Nov 2022 Results published in the Retina
    • 01 Nov 2017 Primary endpoint (Complete polyp regression assessed by ICGA at Month 12) has been met, as per results published in the JAMA Ophthalmology.
    • 01 Nov 2017 Primary endpoint (Change from Baseline in in Visual Acuity (Letters) of the Study Eye to Month 12) has been met, as per results published in the JAMA Ophthalmology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top